Senseonics (NYSE:SENS) today presented further positive data evaluating its next-generation Eversense continuous glucose monitoring system.
Germantown, Md.–based Senseonics presented data from the Promise study at the American Diabetes Association Virtual 81st Annual Scientific Sessions. The data adds to positive results already presented by the company at the beginning of this month that demonstrated high levels of accuracy.
Barbara Davis Center (University of Colorado, Denver) professor of medicine and principal investigator Dr. Satish Garg presented the Eversense data, which, according to a news release, demonstrated matching performance levels compared to the current 90-day sensor available in the U.S., but with reduced calibration, down to one per day, with duration extended to 180 days.
Accuracy measurements included a mean absolute relative difference (MARD) of 9.1% for the primary sensor and confirmed hypoglycemia alert detection rates at 60 mg/dL of 87% and at 70 mg/dL of 93%.
In a subset of 43 modified sensors, the MARD registered at 8.5% and the confirmed hypo alert detection rates at 60 mg/dL and 70 mg/dL were 90% and 94%, respectively.
Senseonics’ Eversense CGM system offers a fluorescence-based sensor, a smart transmitter worn over the sensor for facilitating data communication and a mobile app that displays glucose values, trends and alerts. The company touts it as the first CGM system to feature a smart transmitter that gives wearers discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor.
